Nancy U. Lin, MD

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

In a video interview, Nancy U. Lin, MD, discussed the DESTINY-Breast12 trial in progress presented at the virtual ESMO Congress.

Nancy U. Lin, MD, spoke with Healio about the advances and challenges in the treatment of HER2-positive metastatic breast cancer.

Despite the phase 3 study IPATunity130 demonstrating negative results, the presentation of the data at San Antonio Breast Cancer Symposium 2020 will still be “interesting,” according to Nancy U. Lin, MD.

In this video, Nancy U. Lin, MD, discussed abstracts in immunotherapy presented at the San Antonio Breast Cancer Symposium 2020.

A phase 3 clinical trial, CONTESSA, investigated the treatment of HER2negative, HRpositive metastatic breast cancer in patients who previously received taxane, and results were presented at this year’s San Antonio Breast Cancer Symposium.